Literature DB >> 15018974

Development of novel 5-FU-loaded poly(methylidene malonate 2.1.2)-based microspheres for the treatment of brain cancers.

Elvire Fournier1, Catherine Passirani, Nathalie Colin, Pascal Breton, Serge Sagodira, Jean-Pierre Benoit.   

Abstract

In order to treat malignant brain tumors by local delivery of antineoplastic agents, the feasibility of 5-fluorouracil (5-FU)-sustained release biodegradable microspheres with a novel material, poly(methylidene malonate 2.1.2), was investigated using an emulsion/extraction method. This polymer was expected to present a slow degradation rate, thus leading to a long term local delivery system. Microparticles were successfully obtained and characterized in terms of drug loading, size, morphology and release profile. The size of the particles was between 40 and 50 microm, which was compatible with a stereotactic injection through a needle. Sufficient drug loadings were obtained (i.e. compatible with the preparation of therapeutic 5-FU doses in a minimal volume of injection), and perfectly spherical microspheres were observed. The respective influences of the polymer molecular weight, the polymer concentration, and the emulsion time on the release profiles were studied using a 2(3) factorial design. In the same objective, the solvent extraction time was extended while keeping all the previous parameters fixed at their optimal values. The in vitro study of these different parameters allowed a reduction of the initial burst release, with a percentage of 5-FU released after 24 h that was lowered from 90 to 65%, and the achievement of a long term drug delivery system, since the release was still ongoing after 43 days. Moreover, the microparticles could be gamma-sterilized (25 kGy) without modification of the release kinetics. Thus, the requested specifications to perform animal experiments were attained.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15018974     DOI: 10.1016/S0939-6411(03)00146-2

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  6 in total

1.  A review of the biocompatibility of implantable devices: current challenges to overcome foreign body response.

Authors:  Yoshinori Onuki; Upkar Bhardwaj; Fotios Papadimitrakopoulos; Diane J Burgess
Journal:  J Diabetes Sci Technol       Date:  2008-11

2.  Polymerized β-Cyclodextrin-Based Injectable Hydrogel for Sustained Release of 5-Fluorouracil/Methotrexate Mixture in Breast Cancer Management: In Vitro and In Vivo Analytical Validations.

Authors:  Saud Almawash; Mohamed A El Hamd; Shaaban K Osman
Journal:  Pharmaceutics       Date:  2022-04-08       Impact factor: 6.525

3.  Molecularly imprinted polymers for 5-fluorouracil release in biological fluids.

Authors:  Francesco Puoci; Francesca Iemma; Giuseppe Cirillo; Nevio Picci; Pietro Matricardi; Franco Alhaiqu
Journal:  Molecules       Date:  2007-04-18       Impact factor: 4.411

4.  Biological evaluation of 5-fluorouracil nanoparticles for cancer chemotherapy and its dependence on the carrier, PLGA.

Authors:  Lekha Nair K; Sankar Jagadeeshan; S Asha Nair; G S Vinod Kumar
Journal:  Int J Nanomedicine       Date:  2011-08-17

Review 5.  Novel strategies to improve the anticancer action of 5-fluorouracil by using drug delivery systems.

Authors:  José L Arias
Journal:  Molecules       Date:  2008-10-01       Impact factor: 4.411

6.  Pharmacokinetic variables of medium molecular weight cross linked chitosan nanoparticles to enhance the bioavailability of 5-fluorouracil and reduce the acute oral toxicity.

Authors:  Aisha Sethi; Mahmood Ahmad; Tayyaba Huma; Waqas Ahmad
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.819

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.